Please assess the completion status of the following clinical trial:

Trial Title: IMPACT Study: A Study of Valcyte (Valganciclovir) for Prevention of Cytomegalovirus Disease (CMV) in Kidney Allograft Recipients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* ≥ 16 years of age~* CMV seronegative recipient of primary or secondary renal allograft from a living or cadaveric seropositive donor~* Adequate hematological and renal function~* Patients and partners must agree to maintain effective birth control for 90 days following cessation of study medication~Exclusion Criteria:~* CMV disease, or receipt of anti-CMV therapy within 30 days prior to screening~* Multi-organ transplant recipient~* Hepatitis B, hepatitis C or HIV positive~* Women who are pregnant or lactating

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Valganciclovir up to 100 days (Type: EXPERIMENTAL): Valganciclovir for up to 100 days post kidney transplant
- Valganciclovir up to 200 days (Type: ACTIVE_COMPARATOR): Valganciclovir for up to 200 days post kidney transplant

Based on this trial design, predict the completion outcome and termination type (if applicable).